AT-1965
IND- Indications
- Triple negative breast cancer, Melanoma, Lung cancer, Colorectal cancer
Company intelligence / Profile preview
Akamara Therapeutics
Cambridge, Massachusetts, United Statesremuscap.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Akamara Therapeutics develops novel small molecule immunotherapies targeting B-cells using supramolecular structures. Its lead candidate, AT‑1965, has demonstrated tumor regression and immune memory induction in preclinical models of triple negative breast cancer and other solid tumors. The company completed a successful pre‑IND meeting with the FDA and planned to initiate clinical development by end of 2020. No published human data yet.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesSupramolecular structures
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Akamara Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akamara Therapeutics.